Last reviewed · How we verify
BTV100 High dose
BTV100 is a monoclonal antibody targeting CD19.
BTV100 is a monoclonal antibody targeting CD19. Used for Relapsed or refractory B-cell non-Hodgkin lymphoma, Chronic lymphocytic leukemia.
At a glance
| Generic name | BTV100 High dose |
|---|---|
| Sponsor | BioTheraVision, Inc. |
| Drug class | CD19-targeting monoclonal antibody |
| Target | CD19 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
BTV100 works by binding to CD19 on the surface of B cells, marking them for destruction by the immune system. This leads to a reduction in B cell count and subsequent decrease in B cell-related diseases.
Approved indications
- Relapsed or refractory B-cell non-Hodgkin lymphoma
- Chronic lymphocytic leukemia
Common side effects
- Neutropenia
- Thrombocytopenia
- Anemia
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BTV100 High dose CI brief — competitive landscape report
- BTV100 High dose updates RSS · CI watch RSS
- BioTheraVision, Inc. portfolio CI